UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/922,233	08/03/2001	Simon Erani	4061.007	8232
Morris E. Cohe	7590 03/16/200 <b>n</b>	EXAMINER		
Suite 217	and Avanua	KIM, JENNIFER M		
1122 Coney Island Avenue Brooklyn, NY 11230-2345			ART UNIT	PAPER NUMBER
•			1617	
			MAIL DATE	DELIVERY MODE
			03/16/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	09/922,233	ERANI, SIMON			
Office Action Summary	Examiner	Art Unit			
	JENNIFER MYONG M. KIM	1617			
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period  - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be time will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	lely filed the mailing date of this communication. (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 28 C	october 2008				
,	s action is non-final.				
<i>i</i>	/ <del></del>				
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4)  Claim(s) <u>1-41</u> is/are pending in the application 4a) Of the above claim(s) is/are withdra 5)  Claim(s) is/are allowed. 6)  Claim(s) is/are rejected. 7)  Claim(s) is/are objected to. 8)  Claim(s) <u>1-41</u> are subject to restriction and/or	wn from consideration.				
Application Papers					
9)☐ The specification is objected to by the Examiner.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
Attachment(s)	4) 🖂 Indon dana Comercia	(PTO 412)			
Notice of References Cited (PTO-892)     Notice of Draftsperson's Patent Drawing Review (PTO-948)	4)				
Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)   Solution of Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)   Solution of Information Disclosure Statement(s) (PTO-152)   Solution of Information Disclosure Statement(s) (PTO-152)   Solution of Information Disclosure Statement(s) (PTO-152)   Solution of Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)   Solution of Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)   Solution of Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)   Solution Office of Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)   Solution Office of Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)   Solution Office of Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)   Solution Office of Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)   Solution Office of Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)   Solution Office of Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)   Solution Office of Information Disclosure Statement Statemen					

Application/Control Number: 09/922,233 Page 2

Art Unit: 1617

## **DETAILED ACTION**

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on October 28, 2008 has been entered. Applicant's amendment necessitated following restriction requirement presented in this Office Action. It is noted that restriction requirement can be made at any time before final action when the distinctness and independence of the invention is clear (MPEP 811).

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-40, drawn to a composition and a method for application to human skin to improve the appearance of the skin, comprising:
  - (a) Retinyl Palmitate Polypeptide;
  - (b) Ascorbylmethylsilanol Pectinate;
  - (c) Tocopheryl Polypeptide;
  - (d) Cholecalciferol Polypeptide; and,
  - (e) Niacinamide Polypeptide, classified in class 424, subclass 401.

Art Unit: 1617

II. Claim 41, drawn to a method of treating human skin, comprising the steps of:

Applying a sequence of compositions to the human skin to improve the appearance of the skin, comprising the steps of:

Applying a first composition the human skin, wherein said first composition comprises 2%-20% glycolic acid; applying a second composition to the human skin, wherein said second composition comprises 3-70% Ascorbylmethylsilanol Pectinate; and, applying a third composition to the human skin, wherein said third composition comprises a mixture of Retinyl Palmitate Polypeptide, Ascorbylmethylsilanol Pectinate, Tocopheryl Polypeptide, cholescalciferol Polypeptide, and Niacinamide Polypeptide, classified in class 514, subclasses 845 and 847.

The inventions are distinct, each from the other because of the following reasons:

Inventions Group I and Group II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, the different inventions have different designs and mode of operation because the composition of Group I involves the employment of a single composition involving a single application, while the composition of Group II involves three different compositions requiring a three steps of application.

Restriction for examination purposes as indicated is proper because all these inventions listed in this action are independent or distinct for the reasons given above

and there would be a serious search and examination burden if restriction were not required because one or more of the following reasons apply:

- (a) the inventions have acquired a separate status in the art in view of their different classification;
- (b) the inventions have acquired a separate status in the art due to their recognized divergent subject matter;
- (c) the inventions require a different field of search (for example, searching different classes/subclasses or electronic resources, or employing different search queries);
- (d) the prior art applicable to one invention would not likely be applicable to another invention;
- (e) the inventions are likely to raise different non-prior art issues under 35 U.S.C.101 and/or 35 U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement

Art Unit: 1617

will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention.

If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention.

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

## Communication

Any inquiry concerning this communication or earlier communications from the examiner should be directed to JENNIFER M. KIM whose telephone number is (571)272-0628. The examiner can normally be reached on Monday through Friday 6:30 am to 3 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 09/922,233 Page 6

Art Unit: 1617

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/JENNIFER M KIM/ Primary Examiner, Art Unit 1617

Jmk March 12, 2009